IMGN - ImmunoGen stock gains 7% amid Q3 report positive study results
2023-11-02 12:43:14 ET
More on ImmunoGen
- Analyzing The Acquisition Potential Of ImmunoGen
- ImmunoGen: Takeda Swoops For Slice Of Elahere - Adding To Valuation Uncertainty?
- ImmunoGen Stock Falls, Elahere Growth Contrasts (Rating Upgrade)
- ImmunoGen Q3 2023 Earnings Preview
- ImmunoGen's ovarian cancer medication accepted for EU review
For further details see:
ImmunoGen stock gains 7% amid Q3 report, positive study results